This has important implications for cancer therapy, as it could explain how chemotherapeutic agents such as cisplatin affect EGFR signalling, contributing to chemotherapy resistance and making tumours refractory to antibody therapies targeting the extracellular domain of EGFR. Here, EGFR is linked to neoplasm.